The group's principal activities are to develop and commercialize drugs for the treatment of cancer. The group is presently involved in the clinical developments of the anti-cancer drug phenoxodiol. The group has been formed to commercialize new family of chemicals known as multiple signal transduction regulators (mstrs). The group is in its development stage and phase ii trials of the drug phenoxodiol. The phenoxodiol appears to target a number of key components involved in cancer cell survival and proliferation with little or no effect on normal cells based on the emerging field of signal transduction regulation, which is the regulation of the chemical signals within cells that control specific cell functions. It has spun off from novogen limited its parent company.
